Buy Houlihan Lokey Ahead of a Debt-Driven Restructuring Wave

Hook and thesis

Debt markets are creaking. Recent data show growing stress in private credit concentrated among smaller borrowers, and that is exactly the kind of environment that enlarges the addressable market for Houlihan Lokey's restructuring franchise. HLI is not a generic investment bank; it has a leading franchise in financial restructuring and valuation advisory that tends to see both revenue and fee leverage when default volumes rise. Put simply: more distressed credits should translate into more advisory mandates and outsized fee capture for HLI.

This is an actionable buy idea. The stock trades near $128.39 after a YTD pullback of roughly 21%. The company carries a roughly $8.97 billion market cap, generates strong free cash flow (about $484.6 million), and still shows attractive margins on advisory work. If the wave of private-credit stress continues and HLI converts backlog into mandates, the stock can re-rate meaningfully. My recommended trade: enter at $128.39, stop at $112.83, target $165 over a long-term (180 trading days) horizon.

What Houlihan Lokey does and why it matters

Houlihan Lokey is a specialized investment bank with three revenue pillars: Corporate Finance, Financial Restructuring, and Financial Valuation & Advisory. Restructuring is not incidental here - it is a core competency and the firm is often a first-call advisor in complex creditor-debtor negotiations, chapter proceedings, and recapitalizations.

The market should care because advisory economics in restructuring are countercyclical to the broader M&A market: when capital markets slow and defaults rise, restructuring advisory can both replace lost M&A fees and expand overall fee pools. Recent commentary from the company highlights rising private-credit stress among smaller borrowers, with sub-$100M EBITDA cohorts showing higher default rates and significant marks in loans trading below par. That profile points directly to more opportunities for HLI to advise on workouts, restructurings, and sales of distressed assets.

Evidence and numbers

Here are the concrete metrics that matter:

• Current price: $128.39.
• Market cap: $8.97 billion.
• Enterprise value: $8.23 billion.
• Reported trailing earnings per share: $5.81, giving a P/E of roughly 22.
• Free cash flow last reported: $484.6 million, supporting a healthy cash generation profile.
• Dividend: $0.70 per share paid quarterly; yield around 2%.
• Valuation multiples: price-to-book roughly 4.0, EV/EBITDA about 13.3.
• 52-week range: $112.83 to $204.18.

Operationally, HLI has shown mixed near-term revenues in Corporate Finance but has a durable backlog. Recent headlines note a 24% drop in Corporate Finance revenue YTD and sharp declines in technology-related revenues, but restructuring strength and a record backlog in parts of the business remain supportive. The firm also benefits from relatively light leverage on its balance sheet and a current ratio around 1.06, which reduces financial fragility and preserves optionality to ramp up staff and invest in deal capture during stressful credit cycles.

Valuation framing

At a market cap near $9 billion and EV around $8.23 billion, HLI sits at about 13.3x EV/EBITDA and ~22x trailing EPS. That multiple reflects both the high-quality advisory franchise and cyclicality risk. For context, HLI traded materially higher during the 2024-2025 peak of M&A activity (52-week high $204.18), but today's price includes a sizable haircut after disappointing quarters and sector-wide weakness.

Two valuation angles are important:

• If restructuring activity accelerates, fee pools expand and HLI's operating leverage can push margins and EPS higher, justifying a multiple expansion back toward its historical premium. That path supports our $165 target over the next 180 trading days.
• If the macro stabilizes and M&A recovers instead of defaults rising, HLI can still benefit from steady Corporate Finance fees, but upside will be more muted and slower, keeping multiples range-bound.

Catalysts

• Rising private-credit defaults and distressed loan volume - more advisory mandates and higher fee capture.
• Q3 2026 earnings (10/28/2026) - consensus expects EPS near $1.58 for the quarter; a beat could trigger an immediate re-rating.
• Realization of backlog into closed mandates - conversion of recorded backlog into revenue is a near-term earnings lever.
• Industry consolidation or large sell-side engagements that favor boutiques - HLI often wins high-complexity assignments.

Trade plan (actionable)

Entry: $128.39 (current market price).
Stop-loss: $112.83 (52-week low).
Target: $165.00.
Time horizon: long term (180 trading days). Expect this trade to play out over roughly 6-9 months because restructuring work takes time to surface in fees and for the market to re-rate HLI on sustained win rates and backlog conversion.

Rationale: The entry sits near a recent consolidation range and offers a favorable risk-reward when measured to the 52-week low stop. The $165 target sits well below the prior high of $204.18, giving room for a meaningful rerating without assuming a full reversion to the peak M&A bubble levels. Keep position sizing disciplined; this is a conviction trade on a structural sector shift, not a short-term momentum play.

Technical and sentiment signals

Technicals are neutral-to-constructive: 10- and 20-day SMAs are near current price, RSI around 48.6 indicates no overbought condition, and MACD shows bullish momentum. Short interest has been elevated recently with days-to-cover in the 2.6 range on the latest settlement, which can amplify moves in either direction during news-driven windows such as the upcoming earnings release.

Risks and counterarguments

• Macro stabilizes, defaults do not rise. If credit stress eases and private-credit spreads compress, restructuring opportunities could remain muted, removing the primary upside catalyst.
• Execution risk on backlog conversion. Record backlog is only valuable if it converts into closed mandates and fees; extended sales cycles or cancellations would pressure near-term revenue.
• Legal and reputational risks. A shareholder investigation or litigation could distract management and impose costs; this remains a headline risk that can move the stock independently of fundamentals.
• Concentration in cyclical segments. Corporate Finance has shown steep revenue declines in recent quarters, and a prolonged slowdown in M&A or ECM/DCM would weigh on aggregate results.
• Valuation compression. Even with good top-line, market multiples can compress in risk-off environments, limiting upside for the stock despite operational improvements.

Counterargument: One could argue HLI is priced to reflect cyclical headwinds and that the market already discounts a rise in restructuring activity. If private-credit stress is concentrated in smaller loan pools and larger corporates remain healthy, revenue from restructuring may not scale enough to justify an outsized rerating. In that scenario, HLI could underperform while the market waits for a broader recovery in Corporate Finance.

Why I still prefer the long here

Houlihan Lokey has a rare structural specialty in distressed advisory and valuation that is explicitly countercyclical. The firm generates strong free cash flow and carries a valuation that still allows for meaningful upside if restructuring mandates grow. The short-interest profile and current technical setup mean positive earnings or mandate announcements could produce outsized moves. The trade is therefore a tactical, event-aware long that pairs an attractive optionality on rising defaults with disciplined risk controls.

What would change my mind

I will rethink this recommendation if any of the following occur:

• Evidence that private-credit stress is abating across all borrower cohorts rather than just small pockets. If default curves reverse substantially, the restructuring opportunity shrinks.
• Consecutive quarters of weaker-than-expected backlog conversion or persistent margin erosion in advisory fees.
• Material negative legal outcomes from shareholder actions that impose significant cash costs or reputational damage.

Conclusion

Houlihan Lokey is a good candidate for a trade that leans into a worsening credit cycle. The firm has the domain expertise, balance-sheet flexibility, and cash generation profile to profit from a rise in distressed assignments. Buy at $128.39, stop at $112.83, and target $165 over a long-term (180 trading days) horizon, with careful position sizing and attention to the Q3 print on 10/28/2026 and ongoing private-credit stress indicators.

Key reference stats